Patients with suspected community-onset sepsis accounted for half of total inpatient antipseudomonal beta-lactam antibiotic and anti–MRSA antibiotic days.
The two studies indicate that continuous infusions of beta-lactam antibiotics reduce the risk of mortality in critically ill sepsis patients.
Administering antibiotics more than 5.5 hours after emergency department arrival was associated with increased odds of 3- and 30-day mortality.
Researchers found in-hospital mortality was higher at safety-net hospitals than non–safety-net hospitals, but 30-day mortality was similar.
The maternal vaccine will target neonatal sepsis caused by Klebsiella pneumononiae.
In patients with suspected sepsis, the use of piperacillin-tazobactam was associated with a 5% increase in 90-day mortality compared with cefepime.
The study found that the number of newborns exposed to antibiotics in Swedish neonatal units is higher than it should be, given the low prevalence of early-onset sepsis.
Delayed care, resource constraints, and emergency department crowding by COVID-19 patients likely contributed to the worse outcomes, the authors say.
Danish research and development company GlyProVac will receive $467,000 to develop a maternal vaccine that targets a leading cause of neonatal sepsis.
New data from a study in low- and middle-income countries shows a dose of azithromycin before planned vaginal delivery saves more than $32,000 per 100,000 pregnancies.
